NEUMORA THERAPEUTICS, INC. Research and Development Expense
NEUMORA THERAPEUTICS, INC. (NMRA) reported Research and Development Expense of $29.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- NEUMORA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $29.28M, a 24.38% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $38.60M, a 25.99% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $44.67M, a 2.71% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $40.52M, a 33.17% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. research and development expense for fiscal 2025 was $176.06M, a 12.37% decline from fiscal 2024.
- NEUMORA THERAPEUTICS, INC. research and development expense for fiscal 2024 was $200.93M, a 40.79% increase from fiscal 2023.
- NEUMORA THERAPEUTICS, INC. research and development expense for fiscal 2023 was $142.72M, a 55.55% increase from fiscal 2022.
- NEUMORA THERAPEUTICS, INC. research and development expense for fiscal 2022 was $91.75M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $29.28M 10-Q · filed 2026-08-14 | $67.88M 10-Q · filed 2026-08-14 | $112.55M derived: sum of 3 quarters · filed 2026-08-14 | $153.07M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $38.60M 10-Q · filed 2026-05-07 | $83.27M derived: sum of 2 quarters · filed 2026-05-07 | $123.79M derived: sum of 3 quarters · filed 2026-05-07 | $162.51M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $44.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $85.19M derived: sum of 2 quarters · filed 2026-03-30 | $123.91M derived: sum of 3 quarters · filed 2026-08-14 | $176.06M 10-K · filed 2026-03-30 |
| 2025-09-30 | $40.52M 10-Q · filed 2025-11-06 | $79.24M derived: sum of 2 quarters · filed 2026-08-14 | $131.40M 10-Q · filed 2025-11-06 | $177.31M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $38.72M 10-Q · filed 2026-08-14 | $90.88M 10-Q · filed 2026-08-14 | $136.79M derived: sum of 3 quarters · filed 2026-08-14 | $197.42M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $52.15M 10-Q · filed 2026-05-07 | $98.06M derived: sum of 2 quarters · filed 2026-05-07 | $158.69M derived: sum of 3 quarters · filed 2026-05-07 | $207.32M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $45.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $106.54M derived: sum of 2 quarters · filed 2026-03-30 | $155.17M derived: sum of 3 quarters · filed 2026-03-30 | $200.93M 10-K · filed 2026-03-30 |
| 2024-09-30 | $60.63M 10-Q · filed 2025-11-06 | $109.26M derived: sum of 2 quarters · filed 2025-11-06 | $155.01M 10-Q · filed 2025-11-06 | $193.88M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $48.63M 10-Q · filed 2025-08-06 | $94.39M 10-Q · filed 2025-08-06 | $133.25M derived: sum of 3 quarters · filed 2025-08-06 | $174.85M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $45.76M 10-Q · filed 2025-05-12 | $84.62M derived: sum of 2 quarters · filed 2025-05-12 | $126.22M derived: sum of 3 quarters · filed 2025-05-12 | $158.99M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $38.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $80.47M derived: sum of 2 quarters · filed 2025-03-03 | $113.23M derived: sum of 3 quarters · filed 2025-03-03 | $142.72M 10-K · filed 2025-03-03 |
| 2023-09-30 | $41.60M 10-Q · filed 2024-11-12 | $74.37M derived: sum of 2 quarters · filed 2024-11-12 | $103.86M 10-Q · filed 2024-11-12 | $127.38M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $32.77M 10-Q · filed 2024-08-06 | $62.25M 10-Q · filed 2024-08-06 | $85.78M derived: sum of 3 quarters · filed 2025-03-03 | $108.33M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $29.48M 10-Q · filed 2024-05-07 | $53.01M derived: sum of 2 quarters · filed 2025-03-03 | $75.56M derived: sum of 3 quarters · filed 2025-03-03 | |
| 2022-12-31 | $23.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $46.07M derived: sum of 2 quarters · filed 2025-03-03 | $91.75M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $22.55M 10-Q · filed 2023-11-01 | $68.23M 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |